Astria Therapeutics, Inc.
NASDAQ:ATXS
Overview | Financials
Company Name | Astria Therapeutics, Inc. |
Symbol | ATXS |
Currency | USD |
Price | 9.15 |
Market Cap | 516,372,930 |
Dividend Yield | 0% |
52-week-range | 6.58 - 16.9 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Ms. Jill C. Milne Ph.D. |
Website | https://www.astriatx.com |
An error occurred while fetching data.
About Astria Therapeutics, Inc.
Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage for the treatment of
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD